NBRV - Nabriva Therapeutics GAAP EPS of -$0.18 beats by $0.02 revenue of $9.19M beats by $0.66M
- Nabriva Therapeutics press release ( NASDAQ: NBRV ): Q2 GAAP EPS of -$0.18 beats by $0.02 .
- Revenue of $9.19M (+11.5% Y/Y) beats by $0.66M .
- As of June 30, 2022, Nabriva had $20.2 million in cash, cash equivalents and restricted cash.
- Based on its current operating plans, Nabriva expects that its existing cash resources will be sufficient to enable it to fund its operating expenses, debt service obligations and capital expenditure requirements substantially through the fourth quarter of 2022.
For further details see:
Nabriva Therapeutics GAAP EPS of -$0.18 beats by $0.02, revenue of $9.19M beats by $0.66M